COPD Antibody (A-3): sc-514104
- COPD Antibody (A-3) is a mouse monoclonal IgG2b κ, cited in 2 publications, provided at 200 µg/ml
- specific for an epitope mapping between amino acids 377-401 near the C-terminus of COPD of human origin
- recommended for detection of COPD of mouse, rat and human origin by WB, IP, IF and ELISA
- m-IgG2b BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for COPD Antibody (A-3) for WB applications. These reagents are now offered in bundles with COPD Antibody (A-3) (see ordering information below).
COPD Antibody (A-3) is a mouse monoclonal IgG2b antibody that detects COPD in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). COPD, or coatomer protein complex subunit delta, plays a crucial role in the formation of non-Clathrin coat protein I-coated vesicles, which are essential for membrane and vesicular trafficking within the early secretory pathway. These vesicles facilitate retrograde transport from the Golgi apparatus back to the endoplasmic reticulum, as well as intra-Golgi transport, thereby maintaining cellular homeostasis and proper protein sorting. The structure of the coatomer complex, which consists of two subcomplexes, is vital for its function; the first subcomplex includes the β-, γ-, δ-, and ζ-COP subunits, while the second comprises the α-COP, β′-COP, and ε-COP subunits. This intricate assembly allows for the dynamic formation and disassembly of vesicles, ensuring efficient transport processes that are critical for cellular function and communication. Anti-COPD antibody (A-3) is an invaluable tool for researchers studying the mechanisms of vesicular transport and the role of coatomer proteins in various physiological and pathological contexts.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
COPD Antibody (A-3) References:
- COPD exacerbations. | Burt, L. and Corbridge, S. 2013. Am J Nurs. 113: 34-43; quiz 44. PMID: 23334561
- Asthma and COPD overlap pathophysiology of ACO. | Hikichi, M., et al. 2018. Allergol Int. 67: 179-186. PMID: 29550368
- An underestimated comorbidity of COPD: Thyroid dysfunction. | Akpınar, EE. 2019. Tuberk Toraks. 67: 131-135. PMID: 31414644
- ACO (Asthma-COPD Overlap) Is Independent from COPD: The Case in Favour. | Calverley, PMA. and Walker, PP. 2021. Diagnostics (Basel). 11: PMID: 34208874
- Hypercoagulable State in COPD-A Comprehensive Literature Review. | Kyriakopoulos, C., et al. 2021. Diagnostics (Basel). 11: PMID: 34441381
- Blood eosinophils in COPD: friend or foe? | Papaporfyriou, A., et al. 2022. Expert Rev Respir Med. 16: 35-41. PMID: 34821191
- The Burden of COPD in China and Its Provinces: Findings From the Global Burden of Disease Study 2019. | Yin, P., et al. 2022. Front Public Health. 10: 859499. PMID: 35757649
- Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy. | Papaporfyriou, A., et al. 2023. Life (Basel). 13: PMID: 37374082
- Current Progress of COPD Early Detection: Key Points and Novel Strategies. | Lin, CH., et al. 2023. Int J Chron Obstruct Pulmon Dis. 18: 1511-1524. PMID: 37489241
- N-acetylcysteine Treatment in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis/Pre-COPD: Distinct Meta-analyses. | Papi, A., et al. 2024. Arch Bronconeumol. 60: 269-278. PMID: 38555190
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
COPD Antibody (A-3) | sc-514104 | 200 µg/ml | $322.00 | |||
COPD Antibody (A-3): m-IgGκ BP-HRP Bundle | sc-536223 | 200 µg Ab; 40 µg BP | $361.00 | |||
COPD Antibody (A-3): m-IgG2b BP-HRP Bundle | sc-549525 | 200 µg Ab; 10 µg BP | $361.00 | |||
COPD (A-3) Neutralizing Peptide | sc-514104 P | 100 µg/0.5 ml | $69.00 |